CardioSource WorldNews July 2015 | Page 8

W
E
N

Add Corlanor® to maximally tolerated doses of beta-blockers and help
give appropriate patients with stable, symptomatic chronic heart failure...

MORE HOME.
For patients with stable, symptomatic chronic HF with LVEF ≤ 35% and in sinus rhythm with resting heart rate ≥ 70 bpm:

Corlanor® significantly reduced the relative risk of hospitalization
for worsening HF or CV death by 18% (4.2% ARR; P < 0.0001)
1, 2

– Composite endpoint result reflected only a reduction in the risk of hospitalization for
worsening HF with no favorable effect on CV death
Indication
Corlanor® (ivabradine) is indicated to reduce the risk of
hospitalization for worsening heart failure in patients with
stable, symptomatic chronic heart failure with left ventricular
ejection fraction ≤ 35%, who are in sinus rhythm with resting
heart rate ≥ 70 beats per minute and either are on maximally
tolerated doses of beta-blockers or have a contraindication
to beta-blocker use.
Important Safety Information
Contraindications: Corlanor® is contraindicated in patients
with acute decompensated heart failure, blood pressure
< 90/50 mmHg, sick sinus syndrome, sinoatrial block, 3rd
degree atrioventricular block (unless a functioning demand
pacemaker is present), a resting heart rate < 60 bpm prior

© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-106013

to treatment, severe hepatic impairment, pacemaker
dependence (heart rate maintained exclusively by the
pacemaker), and concomitant use of strong cytochrome
P450 3A4 (CYP3A4) inhibitors.
Fetal Toxicity: Corlanor® may cause fetal toxicity when
administered to a pregnant woman based on embryo-fetal
toxicity and cardiac teratogenic effects observed in animal
studies. Advise females to use effective contraception when
taking Corlanor®.
Atrial Fibrillation: Corlanor® increases the risk of atrial
fibrillation. The rate of atrial fibrillation in patients treated
with Corlanor® compared to placebo was 5% vs. 3.9% per
patient-year, respectively. Regularly monitor cardiac rhythm.
Discontinue Corlanor® if atrial fibrillation develops.